Address
1 Corporate Drive
South San Francisco, CA 94080

Contact
contact@soley.ai

Pipeline

Multiple near-term value catalysts across biopharma and tech arms

Project

Research
Discovery
Lead Selection
Lead Optimization

Research

Discovery

Lead Selection

Lead Optimization

Stress Increasing

SOL-001
Cell cycle inhibitor
SOL-001 Cell cycle inhibitor
NSCLC
NSCLC

NSCLC

Melanoma
Melanoma

Melanoma

Uterine cancer
Uterine cancer

Uterine cancer

Bladder cancer
Bladder cancer

Bladder cancer

SOL-002
Solid tumors
Solid tumors

Solid tumors

SOL-003
Solid tumors
Solid tumors

Solid tumors

SOL-004
Solid tumors
Solid tumors

Solid tumors

Stress Modulating / Tumor Targeting

Radiation Sensitizers
Solid tumors
Solid tumors

Solid tumors

Proteotoxicity
Solid tumors
Solid tumors

Solid tumors

Hypoxia
Solid tumors
Solid tumors

Solid tumors

Stress Reducing

Stress Reversal
Neurodegenerative
Neurodegenerative

Neurodegenerative

Muscular dystrophy
Muscular dystrophy

Muscular dystrophy

Our Science

Our work revolves around the notion that cells are the most powerful computers ever created. Our scientific process, combined with the power of AI/ML, help us gain fluency in this cellular language and revolutionize drug discovery. 

Our science

Dan Von Hoff, M.D.

  • 30+ years pioneer in oncology drug development
  • Distinguished Professor and Physician in Chief, Translational Genomics Research Institute
  • Professor of Medicine at University of Arizona and Mayo Clinic
  • Former National Cancer Advisory Board Member
  • Past President of the American Association for Cancer Research
  • Contributed to development of Abraxane®(nab-paclitaxel), Camptosar® irinotecan, Gemzar® gemcitabine and many other

Afsaneh Naimollah

Linkedin
  • 30+ years of experience corporate finance, strategy advisory and investment banking
  • Executive in Residence, Plug and Play Tech Center
  • Managing Partner, XEN Partners
  • Former Global Head of Barclays Capital Technology Group

Leo Grady, PhD

Linkedin
  • 20+ years of industry experience leading AI/ML, computer vision, and digital health tech
  • Founder and CEO, Stealth AI healthcare company
  • Former CEO of PaigeAI
  • Former SVP of Engineering, Heartflow
  • Founder and CEO of Jona
  • CEO in Residence at Breyer Capital

Fei-Fei Li, PhD

Linkedin
  • Sequoia Professor of Computer Science, Stanford University
  • Co-Director, Stanford Human Centered AI Institute
  • Creator of ImageNet
  • Co-Founder, Chairperson of the Board, AI4ALL
  • Former Chief Scientist of AI/ML, VP Google

Peter Libby, MD

Linkedin
  • Mallinckrodt Professor of Medicine, Cardiovascular Specialist, Harvard Medical School and Brigham and Women’s Hospital
  • World renowned expert in atherosclerosis, cardiovascular medicine and clonal hematopoiesis of indeterminate potential

Keith Flaherty, MD

  • Professor of Medicine, Harvard Medical School
  • Director of Clinical Research, Cancer Center, Massachusetts General Hospital
  • 25+ years expertise in oncology research, drug development, and targeted cancer therapies
  • Co-founder of Loxo Oncology, X4-Pharma, Strata Oncology, Apricity Oncology, Scorpion Therapeutics

Clay Johnston, MD, PhD

Linkedin
  • Professor of Neurology
  • Inaugural Dean, Dell Medical School, UT Austin
  • Former Associate Vice Chancellor of Research, UCSF
  • Co-Founder, Harbor Health

Tony Adamis, MD

  • 30+ years of industry R&D experience
  • Former SVP, Development Innovation, Genentech
  • Co-discovery of VEGF in ocular disease
  • Co-founder, Director, EyeBio

Antoine Yver, MD

Linkedin
  • 30+ years experience and world leader in oncology drug development
  • Board Member, Sanofi
  • Former Head of Oncology Global Medicine Development, AstraZeneca
  • Former Chairman of Development, Centessa
  • Former EVP, Global Head of Oncology R&D, Daiichi Sankyo
  • Contributed to development of Tagrisso® osimertinib, Lynparza® olaparib, Enhertu® trastuzumab deruxtecan and many other

Dan Von Hoff, MD

Co-Founder, CEO, Board Member

Linkedin
  • 30 years of academic experience in patient care, teaching, clinical/basic and stem cell research
  • Expertise in physiologic cellular stress, stem cells, cardiomyocytes, and neuronal cells
  • The Johns Hopkins School of Medicine (1995): M.D.
  • Harvard Medical School / Brigham and Women’s Hospital (1995-2003): internship, residency, chief residency, general and interventional cardiology
  • UCSF (since 2003): Translational Cardiac Stem Cell Program: Founder and Director